Allergan has reallocated $200 million it had slated for a facility expansion in Waco, Tx.
The company announced the expansion plans in 2016, and said it would be used to add 322,000 square feet of manufacturing space, increase production capacity by 50 percent and create about 100 jobs.
But generics competition for its second best-selling product, Restasis, is closing in from companies such as Teva and Mylan, sooner than Allergan expected. Instead of the Waco expansion, the company said it spread out $180 million in investments throughout the rest of its manufacturing network between 2015 and 2018.
Allergan will forgo $4 million in incentives for the planned Waco expansion. The company said, however, that it remains committed to its eye care business, and that it’s also looking to fill about 45 positions throughout its manufacturing sites.